European Commission approves Teva inhaler; Purdue researchers develop new cancer detection method; Alnylam releases new RNAi data;

> The European Commission granted Teva Pharmaceuticals permission to market its DuoResp Spiromax multi-dose dry powder inhaler for the treatment of patients of asthma and chronic obstructive pulmonary disease. Release

> Researchers at Purdue University say they have developed a method of detecting and measuring the aggressiveness of cancer in living cells using gold nanoparticles. Article

> Alnyam released two pieces of data about the use of RNAi for the treatment of TTR-mediated amyloidosis at the International Symposium on Amyloidosis in Indianapolis. It presented the results of its Phase II open-label extension study (release) and pre-clinical data on its research in the arena. Release

Suggested Articles

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.